Here, we investigate if FOXE1 gene dosage is able to influence the outcome of experimental thyroid carcinoma in vivo by using a BRAF oncogene-induced thyroid cancer model with heterozygous Foxe1 knockout allele. This evidence concerns the gene FOXE1 and thyroid gland carcinoma.